手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 医学研究 Volume 2, Issue 3. 2020.
无驱动基因突变晚期非小细胞肺癌的免疫治疗进展
作者 : 熊荣 生
DOI: 10.18686/yxyj.v2i3.21323
全部来源
获取全文
摘要 / Abstract
无
关键词 / Keywords
无
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1].Oshim a Y, Tanim oto T, Yuji K, Tojo A. EGFR-TKI-Associated
  • Interstitial Pneum onitis in Nivolum ab-Treated Patients W ith Non-Sm all
  • Cell Lung Cancer[J]. JAM A Oncol 2018,4(8):1112-1115.
  • [2].Gandhi L, Rodr í guez-Abreu D, Gadgeel S, et al.
  • Pem brolizum ab plus Chem otherapy in M etastatic Non-Sm all-Cell Lung
  • Cancer[J]. N Engl J M ed 2018, 378(22):2078-2092.
  • [3].Paz-Ares L, Luft A, Vicente D, et al. Pem brolizum ab plus
  • Chem otherapy for Squam ous Non-Sm all-Cell Lung Cancer[J]. N Engl J
  • M ed 2018,379(22):2040-2051.
  • [4].M ok TSK, W u YL, Kudaba I, et al. Pem brolizum ab versus
  • chem otherapy for previously untreated, PD-L1-expressing, locally
  • advanced or m etastatic non-sm all-cell lung cancer (KEYNOTE-042): a
  • random ised, open-label, controlled, phase 3 trial[J]. Lancet
  • 2019,393(5):1819-1830.
  • [5].Reck M , Rodr í guez-Abreu D, Robinson AG, et al.
  • Pem brolizum ab versus Chem otherapy for PD-L1-Positive
  • Non-Sm all-Cell Lung Cancer[J]. N Engl J M ed
  • 2016,375(11):1823-1833.
  • [6].Brahm er J, Reckam p KL, Baas P, et al. Nivolum ab versus
  • Docetaxel in Advanced Squam ous-Cell Non-Sm all-Cell Lung Cancer[J].
  • N Engl J M ed 2015; 373(2):123-135.
  • [7].H orn L, Spigel DR, Vokes EE, et al. Nivolum ab Versus
  • Docetaxel in Previously Treated Patients W ith Advanced
  • Non-Sm all-Cell Lung Cancer: Two-Year Outcom es From Two
  • Random ized, Open-Label, Phase III Trials (CheckM ate 017 and
  • CheckM ate 057)[J]. Clin Oncol 2017,35(35):3924-1933.
  • [8].Rittm eyer A, Barlesi F, W aterkam p D, et al. Atezolizum ab versus
  • docetaxel in patients with previously treated non-sm all-cell lung cancer
  • (OAK): a phase 3, open-label, m ulticentre random ised controlled trial[J].
  • Lancet 2017,389(1):255-265.
  • [9].Fehrenbacher L, von Pawel J, Park K, et al. Updated Efficacy
  • Analysis Including Secondary Population Results for OAK: A
  • Random ized Phase III Study of Atezolizum ab versus Docetaxel in
  • Patients with Previously Treated Advanced Non-Sm all Cell Lung
  • Cancer[J].Thorac Oncol 2018,13(8):1156-1170.
  • [10].H erbst RS, Baas P, Kim DW , et al. Pem brolizum ab versus
  • docetaxel for previously treated, PD-L1-positive, advanced
  • non-sm all-cell lung cancer (KEYNOTE-010): a random ised controlled
  • trial[J]. Lancet 2016, 387(10027):1540-1550.
  • [11].Spigel DR, H ussein M A, M cLeod M , et al. Random ized results
  • of fixed-duration (1-yr) vs continuous nivolum ab in patients (pts) with
  • advanced non-sm all cell lung cancer (NSCLC)[J] .Ann Oncol 2017;
  • 28(supp1-5).
  • [12].Kim DW , H erbst RS, Garon EB, et al. Long-term survival in
  • patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall
  • and in pts who com pleted 2 years of pem brolizum ab (pem bro)[J]. Ann
  • Oncol 2018; 29(supp1-8).
  • [13].Gettinger SN, W urtz A, Goldberg SB, et al. Clinical Features
  • and M anagem ent of Acquired Resistance to PD-1 Axis Inhibitors in 26
  • Patients W ith Advanced Non-Sm all Cell Lung Cancer[J]. Thorac Oncol
  • 2018,13(6):831-839.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号